Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN[C@@H](C)[C@H](O)C1=CC=CC=C1
InChI
InChIKey=KWGRBVOPPLSCSI-WPRPVWTQSA-N
InChI=1S/C10H15NO/c1-8(11-2)10(12)9-6-4-3-5-7-9/h3-8,10-12H,1-2H3/t8-,10-/m0/s1
Molecular Formula | C10H15NO |
Molecular Weight | 165.2322 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Ephedrine (l-form) is an alkaloid, which was initially purified from Ephedra plant. The extract form Ephedra has been used in China for medicinal purposes for several thousand years. Ephedrine acts as an agonist at alpha- and beta-adrenergic receptors and indirectly causes the release of norepinephrine from sympathetic neurons. The drug crosses the blood brain barrier and stimulates the central nervous system. Ephedrine products are now banned in many countries, as they are a major source for the production of the addictive compound methamphetamine. FDA has approved ephedrine only for the treatment of clinically important hypotension occurring in the setting of anesthesia.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) |
0.36 µM [EC50] | ||
Target ID: CHEMBL2094251 |
4.95 null [pKi] | ||
Target ID: P08588 Gene ID: 153.0 Gene Symbol: ADRB1 Target Organism: Homo sapiens (Human) |
0.5 µM [EC50] | ||
Target ID: CHEMBL2095158 |
4.83 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | AKOVAZ Approved UseAKOVAZ injection is an alpha- and beta- adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. Launch Date2016 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
79.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
87.4 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
11 mg 3 times / day multiple, oral dose: 11 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
22 mg single, oral dose: 22 mg route of administration: Oral experiment type: SINGLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
6.69 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/973934/ |
11 mg 3 times / day multiple, oral dose: 11 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
EPHEDRINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Effects of two atypical neuroleptics, olanzapine and risperidone, on the function of the urinary bladder and the external urethral sphincter in anesthetized rats. | 2001 |
|
Prevention of generalized reactions to contrast media: a consensus report and guidelines. | 2001 |
|
Recurrent ischaemic colitis associated with pseudoephedrine use. | 2001 Apr |
|
The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood and energy. | 2001 Apr |
|
[Misuse of drugs in recreational sports]. | 2001 Apr |
|
Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
Stimulatory effect of D-ephedrine on beta3-adrenoceptors in adipose tissue of rats. | 2001 Apr 12 |
|
Study on the chiral recognition of the enantiomers of ephedrine derivatives with neutral and sulfated heptakis(2,3-O-diacetyl)-beta-cyclodextrins using capillary electrophoresis, UV, nuclear magnetic resonance spectroscopy and mass spectrometry. | 2001 Apr 20 |
|
Ondansetron versus dehydrobenzoperidol and metoclopramide for management of postoperative nausea in laparoscopic surgery patients. | 2001 Apr-Jun |
|
Intrathecal anaesthesia for the elderly patient: the influence of the induction position on perioperative haemodynamic stability and patient comfort. | 2001 Aug |
|
Dose of prophylactic intravenous ephedrine during spinal anesthesia for cesarean section. | 2001 Aug |
|
Prevention and management of hypotension during spinal anaesthesia for elective Caesarean section: a survey of practice. | 2001 Aug |
|
Hypokalemic metabolic acidosis attributed to cough mixture abuse. | 2001 Aug |
|
Effect of caffeine and ephedrine ingestion on anaerobic exercise performance. | 2001 Aug |
|
Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors. | 2001 Aug 1 |
|
Continuous production of (R)-phenylacetylcarbinol in an enzyme-membrane reactor using a potent mutant of pyruvate decarboxylase from Zymomonas mobilis. | 2001 Aug 20 |
|
The trouble with fat-burner pills. | 2001 Aug 27 |
|
Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients. | 2001 Jan |
|
The effect of betahistine on vestibular habituation: comparison of rotatory and sway habituation training. | 2001 Jul |
|
A stable gas chromatography-mass spectrometry analysis system to characterize Ma Huang products found in health foods and supplements. | 2001 Jul |
|
New observations on the secondary chemistry of world Ephedra (Ephedraceae). | 2001 Jul |
|
Reappearance of cardiac presynaptic sympathetic nerve terminals in the transplanted heart: correlation between PET using (11)C-hydroxyephedrine and invasively measured norepinephrine release. | 2001 Jul |
|
Determination of ephedrines in urine by gas chromatography-mass spectrometry. | 2001 Jul 15 |
|
Perioperative bradycardia and asystole: relationship to vasovagal syncope and the Bezold-Jarisch reflex. | 2001 Jun |
|
Spinal anaesthesia for Caesarean section with bupivacaine 5 mg ml(-1) in glucose 8 or 80 mg ml(-1). | 2001 Jun |
|
Hypotension in spinal anesthesia for cesarean section: a comparison of 0.5% hyperbaric bupivacaine and 5% hyperbaric lidocaine. | 2001 Jun |
|
Cold-syrup induced movement disorder. | 2001 Jun |
|
It's a rave new world: rave culture and illicit drug use in the young. | 2001 Jun |
|
Nutritional supplements as a source for positive doping cases? | 2001 Jun |
|
Stability indicating HPTLC method for the simultaneous determination of pseudoephedrine and cetirizine in pharmaceutical formulations. | 2001 Jun |
|
Evaluation of pre-emptive intramuscular phenylephrine and ephedrine for reduction of spinal anaesthesia-induced hypotension during Caesarean section. | 2001 Mar |
|
Extra-strong graduated compression stocking reduces usage of vasopressor agents during spinal anesthesia for cesarean section. | 2001 May |
|
Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man. | 2001 May |
|
Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. | 2001 May |
|
Seizure activity and unresponsiveness after hydroxycut ingestion. | 2001 May |
|
Determination of ephedrine-type alkaloids in dietary supplements by LC/MS using a stable-isotope labeled internal standard. | 2001 May-Jun |
|
Neuropeptide Y in obese women during treatment with adrenergic modulation drugs. | 2001 May-Jun |
|
Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem? | 2001 May-Jun |
|
Pharmacologic options available to treat symptomatic intradialytic hypotension. | 2001 Oct |
|
The anesthetic management of triplet cesarean delivery: a retrospective case series of maternal outcomes. | 2001 Oct |
|
Time-controlled release pseudoephedrine tablets: bioavailability and in vitro/in vivo correlations. | 2001 Sep |
|
Phenylephrine added to prophylactic ephedrine infusion during spinal anesthesia for elective cesarean section. | 2001 Sep |
|
What constitutes an effective but safe initial dose of lidocaine to test a thoracic epidural catheter? | 2001 Sep |
|
Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. | 2001 Sep |
|
Studying the neuronal side of the synaptic cleft. A tool for investigating the paradox of sympathetic nervous system and heart failure in dilated cardiomyopathy. | 2001 Sep |
|
Kinetic spectrophotometric methods for the quantitation of triprolidine in bulk and in drug formulations. | 2001 Sep |
|
Rapid chiral on-chip separation with simplified amperometric detection. | 2001 Sep 14 |
|
[Risk management by reporting critical incidents. Vitamin K and ephedrine mix-up at a birthing unit]. | 2001 Sep 24 |
|
A history of nebulization. | 2001 Spring |
|
New imaging techniques for cardiovascular autonomic neuropathy: a window on the heart. | 2001 Spring |
Sample Use Guides
The recommended dosages for the treatment of clinically important hypotension in the setting of
anesthesia is an initial dose of 5 to 10 mg administered by intravenous bolus. Administer additional boluses as needed, not to exceed a total dosage of 50 mg.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6111369
Segments of guinea-pig ileum were treated with 10(-6)-10(-3) M ephedrine. Ephedrine inhibited the ileal responses to transmural stimulation in the terminal and the proximal ileum with EC50 values of 57.2 and 85.5 uM, respectively. In the proximal part of the ileum, more than 70% of preparations were relaxed by ephedrine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:21:02 GMT 2023
by
admin
on
Fri Dec 15 17:21:02 GMT 2023
|
Record UNII |
GN83C131XS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
S01FB02
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-ATC |
R01AA03
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-VATC |
QC01CA26
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-ATC |
R03CA02
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
NDF-RT |
N0000175552
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
1.2
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
CFR |
21 CFR 119.1
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-VATC |
QR01AA03
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
CFR |
21 CFR 1315.13
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-ATC |
C01CA26
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-VATC |
QS01FB02
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
CFR |
21 CFR 341.20
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
NCI_THESAURUS |
C87053
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
NDF-RT |
N0000175555
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-VATC |
QG04BX90
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
NDF-RT |
N0000192563
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
DEA NO. |
8113
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
CFR |
21 CFR 341.16
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-ATC |
A08AA56
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
CFR |
21 CFR 1314.20
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-VATC |
QR03CA02
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-ATC |
R01AB05
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
||
|
WHO-VATC |
QR01AB05
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
170951
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
SUB13683MIG
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
DB01364
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
1024
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
100000088883
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
3072
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
D004809
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
206-080-5
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
9294
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
EPHEDRINE
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
8971
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
SUB11936MIG
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
GN83C131XS
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
C472
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
m4933
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | Merck Index | ||
|
299-42-3
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
EPHEDRINE
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | Description: Colourless crystals or a white, crystalline powder; odourless or with a slight, aromatic odour.Solubility: Soluble in water; very soluble in ethanol (~750 g/l) TS; freely soluble in ether R.Category: Antiasthmatic drug.Storage: Ephedrine should be kept in a well-closed container, protected from light.Labelling: The designation on the container should state whether the substance is the hemihydrate or is in the anhydrous form.Additional information. Solutions of Ephedrine in chloroform R may become turbid, especially when the substance contains morethan 10 mg of water per g. Even in the absence of light, Ephedrine is gradually degraded on exposure to a humid atmosphere,the decomposition being faster at higher temperatures. Anhydrous Ephedrine melts at about 38?C, whereas Ephedrinehemihydrate melts at about 42?C. | ||
|
GN83C131XS
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
3966
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | RxNorm | ||
|
556
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
DTXSID0022985
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
CHEMBL211456
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY | |||
|
15407
Created by
admin on Fri Dec 15 17:21:03 GMT 2023 , Edited by admin on Fri Dec 15 17:21:03 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT->PRECURSOR |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SOLVATE->ANHYDROUS |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
PARENT->PRECURSOR |
|
||
|
SALT/SOLVATE -> PARENT |
Definition. Ephedrine contains not less than 98.5% and not more than 101.0% of C10H15NO, calculated with reference to the anhydrous substance.
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
DIASTEREOISOMER -> DIASTEREOISOMER |
|
||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
ASSAY (HPLC)
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|